FI94591C - Menetelmä antiviraalisten ja immunostimuloivien farmaseuttisten koostumusten valmistamiseksi - Google Patents
Menetelmä antiviraalisten ja immunostimuloivien farmaseuttisten koostumusten valmistamiseksi Download PDFInfo
- Publication number
- FI94591C FI94591C FI891145A FI891145A FI94591C FI 94591 C FI94591 C FI 94591C FI 891145 A FI891145 A FI 891145A FI 891145 A FI891145 A FI 891145A FI 94591 C FI94591 C FI 94591C
- Authority
- FI
- Finland
- Prior art keywords
- lysine
- acid
- active ingredients
- fatty acids
- dha
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 23
- 230000000840 anti-viral effect Effects 0.000 title claims description 10
- 230000003308 immunostimulating effect Effects 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 31
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 27
- 239000004472 Lysine Substances 0.000 claims description 24
- 229960003646 lysine Drugs 0.000 claims description 22
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 19
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 18
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 18
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 18
- 235000019766 L-Lysine Nutrition 0.000 claims description 15
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 15
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 239000006014 omega-3 oil Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000018977 lysine Nutrition 0.000 description 9
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- HZRUTVAFDWTKGD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;hydrate Chemical compound O.NCCCC[C@H](N)C(O)=O HZRUTVAFDWTKGD-JEDNCBNOSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229960003104 ornithine Drugs 0.000 description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- -1 channelanine Chemical compound 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MBMBGCFOFBJSGT-SFGLVEFQSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O MBMBGCFOFBJSGT-SFGLVEFQSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000011796 hollow space material Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU881132A HU209973B (en) | 1988-03-09 | 1988-03-09 | Process for production of antiviral and immunstimular pharmaceutical composition |
| HU113288 | 1988-03-09 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI891145A0 FI891145A0 (fi) | 1989-03-09 |
| FI891145L FI891145L (fi) | 1989-09-10 |
| FI94591B FI94591B (fi) | 1995-06-30 |
| FI94591C true FI94591C (fi) | 1995-10-10 |
Family
ID=10952974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI891145A FI94591C (fi) | 1988-03-09 | 1989-03-09 | Menetelmä antiviraalisten ja immunostimuloivien farmaseuttisten koostumusten valmistamiseksi |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPH01316316A (cs) |
| KR (1) | KR890014103A (cs) |
| BE (1) | BE1002890A3 (cs) |
| CA (1) | CA1334576C (cs) |
| CH (1) | CH678918A5 (cs) |
| DE (1) | DE3907649C2 (cs) |
| FI (1) | FI94591C (cs) |
| FR (1) | FR2628324B1 (cs) |
| GB (1) | GB2216418B (cs) |
| HU (1) | HU209973B (cs) |
| IT (1) | IT1229562B (cs) |
| LU (1) | LU87471A1 (cs) |
| NL (1) | NL8900574A (cs) |
| SE (1) | SE8900828L (cs) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU210122B (en) * | 1988-03-23 | 1995-02-28 | Biorex Kutato Fejlesztoe Kft | Process for production of composition against thromboembolytic conditions of circulating system and heart |
| JPH04279523A (ja) * | 1991-01-11 | 1992-10-05 | Nisshin Flour Milling Co Ltd | 免疫賦活油脂加工品 |
| GB9304746D0 (en) * | 1993-03-09 | 1993-04-28 | Scotia Holdings Plc | Treatment of viral infections |
| CA2159116A1 (en) * | 1993-03-26 | 1994-10-13 | Constantin Romulus Dinu | Pharmaceutical composition for the treatment of certain viruses and autoimmune diseases and the procedure of its preparation |
| GB9318611D0 (en) * | 1993-09-08 | 1993-10-27 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| US5767156A (en) * | 1993-10-06 | 1998-06-16 | Peptide Technology Limited | Polyunsaturated fatty acids and uses thereof |
| IT1264987B1 (it) * | 1993-12-14 | 1996-10-17 | Prospa Bv | Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono |
| AUPM906594A0 (en) * | 1994-10-26 | 1994-11-17 | Peptide Technology Limited | Synthetic polyunsaturated fatty acid analogues |
| DE19503993A1 (de) * | 1995-02-08 | 1996-08-14 | Johann Friedrich Dr Med Desaga | Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen |
| US5639858A (en) * | 1995-03-22 | 1997-06-17 | Tularik, Inc. | Human signal transducer and binding assays |
| WO1996030381A1 (en) * | 1995-03-28 | 1996-10-03 | Novo Nordisk A/S | Immunosuppressive agents |
| HU227588B1 (hu) | 2004-12-03 | 2011-09-28 | Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft | Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény |
| US20090192226A1 (en) * | 2007-12-17 | 2009-07-30 | Josef Neu | Materials and Methods for Treatment of Pathological Ocular Vascular Proliferation |
| FR3031451B1 (fr) * | 2015-01-13 | 2018-03-23 | Greentech | Sel d'un triglyceride, preparation et utilisations |
| PL3463310T3 (pl) * | 2016-05-25 | 2023-12-04 | Evonik Operations Gmbh | Tabletki o wysokiej zawartości składników aktywnych soli aminokwasowych kwasów tłuszczowych omega-3 |
| EP3248467A1 (de) * | 2016-05-25 | 2017-11-29 | Evonik Technochemie GmbH | Verfahren zur herstellung einer zusammensetzung enthaltend omega-3-fettsäure-l-lysin-salze |
| WO2019008101A1 (en) | 2017-07-06 | 2019-01-10 | Evonik Technochemie Gmbh | ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS |
| JP7050148B2 (ja) | 2017-08-15 | 2022-04-07 | エボニック オペレーションズ ゲーエムベーハー | オメガ－３脂肪酸アミノ酸塩の有効成分含有量が高い錠剤 |
| WO2021023857A1 (en) | 2019-08-08 | 2021-02-11 | Evonik Operations Gmbh | Solubility enhancement of poorly soluble actives |
| US20220280387A1 (en) | 2019-08-08 | 2022-09-08 | Evonik Operations Gmbh | Down streaming process for the production of polyunsaturated fatty acid salts |
| DE102022003441A1 (de) | 2022-09-17 | 2024-03-28 | Jutta Ibrahim | Nahrungsergänzungsmittel Omega3 und essentielle Aminosäure(n) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1256162A (en) * | 1968-08-16 | 1971-12-08 | Braun Fa B | Improvements in and relating to liquid products for intravenous administration |
| FR2215212B1 (cs) * | 1973-01-18 | 1976-03-05 | Seperic Ch | |
| FR2508797B1 (fr) * | 1981-07-03 | 1986-03-14 | Charles Chany | Medicament comprenant le produit de la reaction d'un acide carboxylique en c1 a c6 sur un amino-acide basique |
| GB2118437B (en) * | 1982-03-01 | 1984-12-12 | Efamol Ltd | Composition for treating alcoholism |
| US4513008A (en) * | 1982-07-30 | 1985-04-23 | The Vinoxen Company, Inc. | Virucidal compositions and therapy |
| DE3229956A1 (de) * | 1982-08-12 | 1984-02-16 | Erichsen, Friedrich Karl, Dr., 2351 Schillsdorf | Arzneimittel mit cytostatischer wirkung |
| DE3514328C1 (de) * | 1985-04-19 | 1986-09-11 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, 6900 Heidelberg | Verwendung von L-Ornithin bei der selektiven Hemmung von cytotoxischen T-Lymphozyten-Effektorzellen |
| AU596880B2 (en) * | 1986-09-17 | 1990-05-17 | Clintec Nutrition Company | Liquid nutritional compositions |
| DE3878812T2 (de) * | 1987-02-20 | 1993-07-22 | Shriners Hospitals For Cripple | Omega-3-fettsaeuren zur behandlung von traumatischen verwundungen. |
| DE3726299A1 (de) * | 1987-06-26 | 1989-02-23 | Dietl Hans | Fettemulsion zur intravenoesen anwendung |
-
1988
- 1988-03-09 HU HU881132A patent/HU209973B/hu unknown
-
1989
- 1989-03-06 CH CH819/89A patent/CH678918A5/de not_active IP Right Cessation
- 1989-03-09 BE BE8900254A patent/BE1002890A3/fr not_active IP Right Cessation
- 1989-03-09 JP JP1055242A patent/JPH01316316A/ja active Pending
- 1989-03-09 CA CA000593270A patent/CA1334576C/en not_active Expired - Fee Related
- 1989-03-09 FI FI891145A patent/FI94591C/fi not_active IP Right Cessation
- 1989-03-09 NL NL8900574A patent/NL8900574A/nl not_active Application Discontinuation
- 1989-03-09 KR KR1019890002920A patent/KR890014103A/ko not_active Withdrawn
- 1989-03-09 IT IT8919704A patent/IT1229562B/it active
- 1989-03-09 LU LU87471A patent/LU87471A1/fr unknown
- 1989-03-09 DE DE3907649A patent/DE3907649C2/de not_active Expired - Fee Related
- 1989-03-09 SE SE8900828A patent/SE8900828L/xx not_active Application Discontinuation
- 1989-03-09 GB GB8905385A patent/GB2216418B/en not_active Expired - Fee Related
- 1989-03-09 FR FR8903085A patent/FR2628324B1/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FI891145L (fi) | 1989-09-10 |
| NL8900574A (nl) | 1989-10-02 |
| SE8900828D0 (sv) | 1989-03-09 |
| KR890014103A (ko) | 1989-10-21 |
| CA1334576C (en) | 1995-02-28 |
| IT1229562B (it) | 1991-09-04 |
| LU87471A1 (fr) | 1990-10-02 |
| IT8919704A0 (it) | 1989-03-09 |
| DE3907649C2 (de) | 1996-07-11 |
| SE8900828L (sv) | 1989-09-10 |
| CH678918A5 (cs) | 1991-11-29 |
| FR2628324B1 (fr) | 1994-05-27 |
| JPH01316316A (ja) | 1989-12-21 |
| FI891145A0 (fi) | 1989-03-09 |
| BE1002890A3 (fr) | 1991-07-16 |
| FR2628324A1 (fr) | 1989-09-15 |
| GB2216418B (en) | 1991-12-11 |
| DE3907649A1 (de) | 1989-09-28 |
| FI94591B (fi) | 1995-06-30 |
| HU209973B (en) | 1995-01-30 |
| HUT60432A (en) | 1992-09-28 |
| GB8905385D0 (en) | 1989-04-19 |
| GB2216418A (en) | 1989-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI94591C (fi) | Menetelmä antiviraalisten ja immunostimuloivien farmaseuttisten koostumusten valmistamiseksi | |
| Stokes et al. | MICROBIOLOGICAL METHODS FOR THE DETERMINATION OF AMINO ACIDS: II. A UNIFORM ASSAY FOR THE TEN ESSENTIAL AMINO ACIDS | |
| FI93949C (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten suolayhdisteiden valmistamiseksi | |
| JPH01121300A (ja) | 乳汁に由来するポリペプチド成長因子 | |
| US5869714A (en) | Salts of omega-3-polyunsaturated fatty acids and pharmaceutical formulations containing them | |
| Buchmüller-Rouiller et al. | Macrophage activation for intracellular killing as induced by calcium ionophore. Correlation with biologic and biochemical events | |
| Ivanovska et al. | Influence of cinnamic acid on lymphocyte proliferation, cytokine release and Klebsiella infection in mice | |
| US20220273597A1 (en) | Agent for preventing, ameliorating, or treating periodontal disease | |
| CN110650970A (zh) | 抗菌肽及其药品 | |
| SE8406555D0 (sv) | A process for obtaining ready-for-fertilization sexual products from sexually mature fish | |
| US6469137B1 (en) | Myelopeptides and their therapeutic use | |
| KR101263963B1 (ko) | 항바이러스 및 면역자극 해산 어류 오일 조성물 | |
| DE68907268D1 (de) | Verwendung von phytinsaeure als antidot gegen alkoholvergiftung. | |
| Funk et al. | Utilization of the L-and DL-isomers of α-keto-β-methylvaleric acid by rats and comparative efficacy of the keto analogs of branched-chain amino acids provided as ornithine, lysine and histidine salts | |
| Ash et al. | Impact of Nippostrongylus brasiliensis (Nematoda) on the serum albumin and amino acid concentrations of rats fed adequate or protein-deficient diets | |
| KR100346334B1 (ko) | 스코폴레틴으로 이루어진 염증 치료용 약제 조성물 | |
| FR2691153A1 (fr) | Dodécapeptides monomère et dimère, utilisation en tant qu'agents anti-mégacaryocytaires. | |
| JPH04330095A (ja) | 生理活性ポリペプチド、その製造法および抗菌剤 | |
| JPH04330096A (ja) | 生理活性ポリペプチド、その製造方法および抗菌剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: BIOREX KFT |